Blood and Bone Marrow Transplantation in India: Past, Present, and Future

Tapan K Saikia

doi:10.4103/ijmpo.ijmpo_159_20

Indian Journal of Medical and Paediatric Oncology, Table of Contents

CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2020; 41(03): 308-311
DOI: 10.4103/ijmpo.ijmpo_159_20

Editorial Commentary

Blood and Bone Marrow Transplantation in India: Past, Present, and Future

Tapan K Saikia

Department of Medical Oncology, Prince Aly Khan Hospital, Mumbai, Maharashtra, India

› Author Affiliations

Abstract

Full Text

References

References
1 de la Morena MT, Gatti RA. A history of bone marrow transplantation. Hematol Oncol Clin North Am 2011; 25: 1-5
2 Barnes DW, Corp MJ, Loutit JF, Neal FE. Treatment of murine leukaemia with X rays and homologous bone marrow; preliminary communication. Br Med J 1956; 2: 626-7
3 Thomas ED, Lochte HLJr, Lu WC, Ferrebee JW. Intravenous infusion of bone marrow in patients receiving radiation and chemotherapy. N Engl J Med 1957; 257: 491-6
4 Thomas ED. A history of haemopoietic cell transplantation. Br J Haematol 1999; 105: 330-9
5 Appelbaum FR. Hematopoietic-cell transplantation at 50. N Engl J Med 2007; 357: 1472-5
6 Saber W, Opie S, Rizzo JD, Zhang MJ, Horowitz MM, Schriber J. Outcomes after matched unrelated donor versus identical sibling hematopoietic cell transplantation in adults with acute myelogenous leukemia. Blood 2012; 119: 3908-16
7 Gluckman E, Ruggeri A, Volt F, Cunha R, Boudjedir K, Rocha V. Milestones in umbilical cord blood transplantation. Br J Haematol 2011; 154: 441-7
8 Advani SH, Saikia TK. Bone marrow transplant in India. Bone Marrow Transplant ation 1994; 13: 731-2
9 Chandy M. Innovative supportive care practices for stem cell transplantation in India. Biol Blood Marrow Transplant 2009; 15: 95-8
10 Mathews V, Srivastava A, Chandy M. Allogeneic stem cell transplantation in thalassemia major. Hematol Oncol N Am 2014; 28: 1187-2000
11 George B, Mathews V, Melinkeri S, Lakshmi KM, Sharma A, Viswabandya A. et al. The use of a fludarabine-based conditioning regimen in patients with severe aplastic anemia-a retrospective analysis from three Indian centers. Clin Transplant 2013; 27: 923-9
12 Mathews V, George B, Viswabandya A, Abraham A, Ahmed R, Ganapule A. et al Improved clinical outcomes of high risk B thalassemia major patients undergoing a HLA matched related alloegeneic stem cell transplant with s treosulfan based conditioning regimen and peripheral blood stem cell grafts. PLoS One 2013; 8: e61637
13 Saikia TK, Parikh PM, Tawde S, Amare-Kadam PS, Rajadhyaksha S, Chhaya S. Allogeneic blood stem cell transplantation in chronic myeloid leukaemia-chronic phase following conditioning with busulphan and cyclophosphamide: A follow up report. Natl Med J India 2004; 17: 71-3
14 Das M, Saikia TK, Advani SH, Parikh PM, Tawde S. Use of a reduced-intensity conditioning regimen for allogeneic transplantation in patients with chronic myeloid leukemia. Bone Marrow Transplant 2003; 32: 125-9
15 Punatar S, Mohite A, Gokarn A, Nayak L, Bonda A, Shanmugam K. et al. Leflunomide for chronic musculoskeletal graft versus host disease following allogeneic hematopoietic stem cell transplant. Bone Marrow Transplant 2020; 55: 467-9
16 Yadav SP. Bone marrow transplantation for primary immune deficiency disorders in India: Past, Present and Future. Indian Pediatr 2018; 55: 657-8
17 Luznik L, O'Donnell PV, Symons HJ, Chen AR, Leffell MS, Zahurak M. et al. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose posttransplant cyclophosphamide. Biol Blood Marrow Transplant 2008; 14: 641-650
18 Wachsmuth LP, Patterson MT, Eckhaus MA, Venzon DJ, Gress RE, Kanakry CG. Posttransplantation cyclophosphamide prevents graft-versus-host disease by inducing alloreactive T cell dysfunction and suppression. J Clin Invest 2019; 129: 2357-73
19 Radich J. Stem cell transplant for chronic myeloid leukemia in the imatinib era. Semin Hematol 2010; 47: 354-61
20 Gokbuget N, Dombert H, Bonifacio M, Reichle A, Graux C, Faul C. et al. Blinatumomab for MRD in adults with B-cell precursor acute lymphoblastic leukemia. Blood 2018; 131: 1522-31
21 Jacoby E. The role of allogeneic HSCT after CAR T cells for acute lymphoblastic leukemia. Bone Marrow Transplant 2019; 54: 810-4
22 Bazarbachi AH, Al HamedR, Malard F, Mohty M, Bazarbachi A. Allogeneic transplant for FLT3 ITD mutated AML: A focus on FLT3 inhibitors before, during, and after transplant. Ther Adv Hematol 2019; 10: 2040620719882666
23 Schroeder T, Rautenberg C, Haas R, Germing U, Kobbe G. Hypomethylating agents for treatment and prevention of relapse after allogeneic blood stem cell transplantation. Int J Hematol 2018; 107: 138-50
24 Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA. et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med 2017; 377: 2531-44
25 Szer J, Weisdorf D, Querol S, Foeken L, Madrigal A. The impact of COVID-19 on the provision of donor hematopoietic stem cell products worldwide: Collateral damage. Bone Marrow Transplant 2020; 23: 1-2 Online ahead of print